Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.38 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.38 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.38 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296294 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1S1PR1S1PR4S1PR3 | |
| SCHEMBL296377 | 0.86 | S1PR1 (0.56) | S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL293675 | 0.86 | SMN1; SMN2 (0.41) | SMN1; SMN2S1PR1S1PR3LMNAKMT2A | |
| SCHEMBL293676 | 0.86 | SMN1; SMN2 (0.41) | SMN1; SMN2S1PR1S1PR3LMNAKMT2A | |
| SCHEMBL295021 | 0.83 | S1PR1 (0.48) | SMN1; SMN2NPC1S1PR1S1PR4S1PR3 | |
| SCHEMBL295020 | 0.83 | S1PR1 (0.48) | SMN1; SMN2NPC1S1PR1S1PR4S1PR3 | |
| SCHEMBL295723 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1S1PR1S1PR3LMNA | |
| SCHEMBL295722 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1S1PR1S1PR3LMNA | |
| SCHEMBL13990376 | 0.79 | S1PR1 (0.51) | S1PR1S1PR4S1PR3S1PR5TDP1 | |
| Hydrochloric Acid SCHEMBL296349 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2NPC1S1PR1S1PR3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636171-B1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | claimed |
| EP-1636171-B1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-7696184-B2 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20070010494-A1 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | NOVARTIS AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1636171-A2 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR | Novartis AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110979-A2 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR | NOVARTIS AG (CH) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010494-A1 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | S1PR1, S1PR3, S1PR2 | SMN1; SMN2 2873/4885NPC1 1423/4885S1PR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.